Pharmaceutical - Bayer

Filter

Current filters:

Bayer

Popular Filters

1 to 25 of 293 results

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

15-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) have recommended…

BayerOncologyPharmaceuticalPricingRegulationUKXofigo

Bayer fails in Indian Nexavar patent appeal

Bayer fails in Indian Nexavar patent appeal

13-12-2014

German pharma major Bayer suffered a significant disappointment on Friday, when India’s Supreme Court…

BayerIndiaLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

Bayer collaborates with DNDi on novel, oral human river blindness treatment

09-12-2014

German pharma major Bayer and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement…

Astellas PharmaBayeremodepsidePharmaceuticalResearchTropical diseases

Roche's Gazyvaro and Bayer’s Adempas approved by Scottish Medicines Consortium

Roche's Gazyvaro and Bayer’s Adempas approved by Scottish Medicines Consortium

08-12-2014

The Scottish Medicines Consortium has decided to grant access to Gazyvaro (obinutuzumab), manufactured…

AdempasBayerCardio-vascularGazyvaroOncologyPharmaceuticalRegulationRoche

Bayer files for European approval of hemophilia A drug BAY 81-8973

06-12-2014

German pharma major Bayer has filed an application for marketing authorization to the European Medicines…

BAY 81-8973BayerEuropeHematologyPharmaceuticalRegulation

Bayer boasts strong R&D pipeline and growth prospects

03-12-2014

German pharma major Bayer gave a spirited presentation of its pipeline candidates in both pharma and…

AdempasBayerEyleaFinancialHematologyOncologyOphthalmicsPharmaceuticalResearchStivargaXareltoXofigo

SMC accepts Eylea and Onglyza for use in NHS Scotland

SMC accepts Eylea and Onglyza for use in NHS Scotland

13-11-2014

The Scottish Medicines Consortium (SMC) has accepted German drugmaker Bayer’s Eylea (aflibercept solution…

AstraZenecaBayerDiabetesEyleaOnglyzaPharmaceuticalRegulationUK

Highlights of EMA Pharmacovigilance unit meeting

09-11-2014

At its meeting last week, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee…

BayerBiogen IdecCSL BehringEuropeHelixateHematologyKogenateNeurologicalPharmaceuticalRegulationTecfidera

Bayer sees strong third-qtr sales and earnings growth

Bayer sees strong third-qtr sales and earnings growth

30-10-2014

Reporting third-quarter 2014 financials this morning, German pharma major Bayer (BAYN: DE) said group…

BayerFinancialPharmaceutical

UK’s NICE backs another use for Bayer’s Xarelto

UK’s NICE backs another use for Bayer’s Xarelto

23-10-2014

In draft guidance published today for consultation, the UK’s health costs watchdog the National Institute…

BayerCardio-vascularPharmaceuticalPricingRegulationUKXarelto

NICE updates guidance for management of multiple sclerosis but does not recommend Bayer's Sativex

NICE updates guidance for management of multiple sclerosis but does not recommend Bayer's Sativex

09-10-2014

The UK’s National Institute for Health and Care Excellence (NICE) has updated its guidance for the…

BayerNeurologicalPharmaceuticalRegulationSativexUK

Bayer’s Jadelle to be listed in New Zealand

Bayer’s Jadelle to be listed in New Zealand

26-09-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

BayerJadelleMarkets & MarketingNew ZealandPharmaceuticalPricingReproductiveWomen's Health

Bayer’s Eylea approved in Japan for myopic CNV

Bayer’s Eylea approved in Japan for myopic CNV

22-09-2014

Bayer Yakuhin, the Japanese health care subsidiary if Germany’s Bayer has received approval from Japan’s…

BayerEyleaJapanOphthalmicsPharmaceuticalRegeneron PharmaceuticalsRegulation

Bayer plans to focus entirely on Life Science businesses

Bayer plans to focus entirely on Life Science businesses

18-09-2014

The board of management of Germany’s Bayer AG plans to focus the Bayer Group entirely on the Life Science…

BayerFinancialGermanyManagementPharmaceutical

Benefit for once-daily Xarelto in the first trial to evaluate prospective use in AF patients undergoing cardioversion

Benefit for once-daily Xarelto in the first trial to evaluate prospective use in AF patients undergoing cardioversion

02-09-2014

German pharma and chemical major Bayer has released results from the X-VeRT* study, demonstrating that…

BayerCardio-vascularPharmaceuticalResearchXarelto

New studies planned to further expand indications for Xarelto

New studies planned to further expand indications for Xarelto

29-08-2014

German pharma major Bayer and partner Janssen Research & Development, a unit of US health care giant…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalResearchXarelto

Imatinib and sunitinib will continue to dominate patient share in GIST treatment

Imatinib and sunitinib will continue to dominate patient share in GIST treatment

11-08-2014

The treatment landscape of gastrointestinal stromal tumors (GIST) will not change dramatically through…

BayerGleevecGlivecMarkets & MarketingNovartisOncologyPfizerPharmaceuticalStivargaSutent

Eylea approved for diabetic macular edema in Europe

Eylea approved for diabetic macular edema in Europe

11-08-2014

The European Commission has approved German pharma major Bayer’s Eylea (aflibercept) injection for…

BayerEuropeEyleaOphthalmicsOphthalmologyPharmaceuticalRegeneronRegulation

Bayer’s 2nd-qtr earnings hit by currency, missing expectations

Bayer’s 2nd-qtr earnings hit by currency, missing expectations

30-07-2014

Germany’s pharma and life sciences major Bayer posted a solid set of second-quarter 2014 financial…

BayerCancerConsumer HealthFinancialGermanyGermanyPharmaceuticalPulmonary hypertension

1 to 25 of 293 results

Back to top